Synergia Medical

Executive Summary

Synergia Medical, based in Liège, Belgium, is a medical device company pioneering next-generation neuromodulation solutions for cardiovascular and peripheral vascular interventions. Founded in 2015, the company leverages its proprietary optoelectronic platform to replace conventional metal components in neurostimulation systems, addressing key limitations such as size, MRI compatibility, and energy efficiency. By combining optics and electronics, Synergia aims to create minimally invasive devices that offer precise stimulation while reducing tissue trauma and enabling compatibility with advanced imaging modalities. This approach positions the company to disrupt the neuromodulation market, which is traditionally dominated by bulky, metal-based implants. With a focus on cardiovascular applications, Synergia's technology could improve outcomes for patients with conditions like hypertension and heart failure, while also expanding into peripheral nerve stimulation for chronic pain and other disorders. Despite operating in a highly regulated space, Synergia Medical's innovative platform has the potential to capture significant market share if clinical validation and regulatory approvals are obtained. The company is likely at a preclinical or early clinical stage, requiring funding to advance its lead product through First-in-Human studies. Success will depend on demonstrating safety and efficacy in patients, securing intellectual property protection, and forging strategic partnerships with device manufacturers or pharmaceutical companies. While no recent funding rounds or partnerships are publicly disclosed, the company's novel approach and experienced founding team suggest strong long-term potential. Investors should monitor upcoming milestones, including initial clinical data and financing activities, which will be critical for de-risking the technology and validating its commercial viability.

Upcoming Catalysts (preview)

• Q2 2027Completion of First-in-Human Study for Lead Optoelectronic Neuromodulation Device40% success
• Q4 2026Series A or Series B Funding Round to Advance Clinical Development60% success
• Q3 2027CE Marking or FDA Breakthrough Device Designation for Vascular Applications30% success